biote Corp. (BTMD)
| Market Cap | 36.95M -57.7% |
| Revenue (ttm) | 178.91M -8.6% |
| Net Income | -1.93M |
| EPS | -0.07 |
| Shares Out | 33.90M |
| PE Ratio | n/a |
| Forward PE | 145.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,125 |
| Open | 1.080 |
| Previous Close | 1.080 |
| Day's Range | 1.080 - 1.120 |
| 52-Week Range | 0.990 - 2.900 |
| Beta | 1.74 |
| Analysts | Strong Buy |
| Price Target | 2.22 (+104.04%) |
| Earnings Date | Nov 4, 2026 |
About BTMD
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice m... [Read more]
Financial Performance
In 2025, biote's revenue was $192.22 million, a decrease of -2.52% compared to the previous year's $197.19 million. Earnings were $27.05 million, an increase of 756.67%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BTMD stock is "Strong Buy." The 12-month stock price target is $2.22, which is an increase of 104.04% from the latest price.
News
Biote price target lowered to $1.20 from $1.50 at B. Riley
B. Riley lowered the firm’s price target on Biote (BTMD) to $1.20 from $1.50 and keeps a Neutral rating on the shares.
Biote reports Q3 EPS 1c vs 22c last year
Reports Q3 revenue $43.3M, consensus $44.01M. “While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more sl...
Biote backs FY26 revenue view above $175M, consensus $177.92M
Backs FY26 adjusted EBITDA view above $25M.
biote Earnings Call Transcript: Q3 2026
Q3 revenue fell 9.6% YoY as procedure revenue remained pressured by recall effects, while supplements grew and gross margin improved sequentially. FY 2026 guidance was maintained as efforts target clinic retention, practitioner engagement, and procedure growth.
biote Earnings release: Q3 2026
biote released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
biote Quarterly report: Q3 2026
biote has published its Q3 2026 quarterly earnings report on November 4, 2026.
Biote Reports Third Quarter 2026 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...
Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practi...
Biote price target lowered to $1.50 from $2 at B. Riley
B. Riley analyst Jeff Van Sinderen lowered the firm’s price target on Biote (BTMD) to $1.50 from $2 and keeps a Neutral rating on the shares.
Biote price target lowered to $2 from $2.50 at TD Cowen
TD Cowen analyst Jonna Kim lowered the firm’s price target on Biote (BTMD) to $2 from $2.50 and keeps a Buy rating on the shares. The firm updated its model…
Biote price target lowered to $2.50 from $3 at Roth Capital
Roth Capital lowered the firm’s price target on Biote (BTMD) to $2.50 from $3 and keeps a Buy rating on the shares.
Biote reports Q2 EPS (23c) vs 10c last year
Reports Q2 revenue $44.2M, consensus $46.08M. “Over the past year Biote (BTMD) has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe...
Biote sees FY26 revenue above $175M, consensus $190.61M
Sees FY26 adjusted EBITDA above $25M
biote Earnings Call Transcript: Q2 2026
Q2 2026 saw a 9.5% revenue decline due to a product recall, with procedure revenue down 13.9% and dietary supplements up 5.7%. Gross margin and adjusted EBITDA fell, while legal expenses spiked but are expected to decrease. Full-year guidance was revised downward.
biote Earnings release: Q2 2026
biote released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
biote Quarterly report: Q2 2026
biote has published its Q2 2026 quarterly earnings report on August 5, 2026.
Biote Reports Second Quarter 2026 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...
Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practi...
Biote appoints Bajaj as Chief Medical Officer
Biote (BTMD) announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj joins Biote following senior leadership roles within NYC Health +…
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Baja...
Biote announces Christensen to step down as CEO, Peterson named interim CEO
Biote (BTMD) announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is s...
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...
Biote reports Q1 EPS 6c, one estimate 8c
Reports Q1 revenue $44.9M, consensus $46.0M. “During the first quarter of 2026, we continued to advance our strategic priorities and remained focused on our key objective of restoring sustainable proc...
Biote sees FY26 revenue over $190M, consensus $191.7M
16:56 EDT Biote (BTMD) sees FY26 revenue over $190M, consensus $191.7M
biote Earnings Call Transcript: Q1 2026
Revenue declined 8.3% year-over-year due to a voluntary recall, impacting both sales and margins, but dietary supplement revenue grew 19.1%. Management expects supply normalization and sales force expansion to drive a return to growth in the second half of 2026.